Sinopep-Allsino Biopharmaceutical Co. Ltd. A Cash Flow Conversion Efficiency

Latest as of September 2025: 0.022x

Sinopep-Allsino Biopharmaceutical Co. Ltd. A cash flow conversion efficiency. Based on the latest financial reports, Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) has a cash flow conversion efficiency ratio of 0.022x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥68.66 Million ≈ $10.05 Million USD) by net assets (CN¥3.13 Billion ≈ $458.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2025)

Cash flow conversion efficiency of Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2025. This chart illustrates how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Sinopep-Allsino Biopharmaceutical Co. Lt for real-time trading data and today's change.

Sinopep-Allsino Biopharmaceutical Co. Ltd. A Cash Flow Conversion Ratio Explained

Sinopep-Allsino Biopharmaceutical Co. Ltd. A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Sinopep-Allsino Biopharmaceutical Co. Ltd. A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sinopep-Allsino Biopharmaceutical Co. Ltd. A ranked by their cash flow conversion efficiency. Also see market cap of Sinopep-Allsino Biopharmaceutical Co. Lt for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
GH Research PLC
NASDAQ:GHRS
-0.042x
Grand Plastic Technology
TWO:3131
-0.024x
Wedge Industrial Co Ltd
SHE:000534
0.006x
São Martinho S.A
SA:SMTO3
0.030x
Teva Pharmaceutical Industries Ltd
TA:TEVA
0.093x
Turning Point Brands Inc
NYSE:TPB
-0.058x
Transwarp Technology (Shanghai) Co. Ltd. A
SHG:688031
N/A
Kontron AG
VI:KTN
-0.006x

Annual Cash Flow Conversion Efficiency for Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2025)

The table below shows the annual cash flow conversion efficiency of Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2025. Review 688076 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥3.00 Billion
≈ $439.25 Million
CN¥681.24 Million
≈ $99.69 Million
0.227x +52.14%
2024-12-31 CN¥2.68 Billion
≈ $392.51 Million
CN¥400.12 Million
≈ $58.55 Million
0.149x -6.75%
2023-12-31 CN¥2.19 Billion
≈ $320.36 Million
CN¥350.21 Million
≈ $51.25 Million
0.160x +951.19%
2022-12-31 CN¥1.92 Billion
≈ $281.67 Million
CN¥29.29 Million
≈ $4.29 Million
0.015x -84.77%
2021-12-31 CN¥1.81 Billion
≈ $264.68 Million
CN¥180.75 Million
≈ $26.45 Million
0.100x -31.72%
2020-12-31 CN¥966.02 Million
≈ $141.36 Million
CN¥141.38 Million
≈ $20.69 Million
0.146x +166.14%
2019-12-31 CN¥838.98 Million
≈ $122.77 Million
CN¥46.14 Million
≈ $6.75 Million
0.055x -55.04%
2018-12-31 CN¥785.38 Million
≈ $114.93 Million
CN¥96.06 Million
≈ $14.06 Million
0.122x +253.60%
2017-12-31 CN¥321.20 Million
≈ $47.00 Million
CN¥11.11 Million
≈ $1.63 Million
0.035x +105.51%
2016-12-31 CN¥34.95 Million
≈ $5.11 Million
CN¥-21.95 Million
≈ $-3.21 Million
-0.628x +59.12%
2015-12-31 CN¥73.32 Million
≈ $10.73 Million
CN¥-112.62 Million
≈ $-16.48 Million
-1.536x +51.62%
2014-12-31 CN¥-21.47 Million
≈ $-3.14 Million
CN¥68.18 Million
≈ $9.98 Million
-3.175x -126.79%
2013-12-31 CN¥3.69 Million
≈ $539.29K
CN¥43.67 Million
≈ $6.39 Million
11.850x --

About Sinopep-Allsino Biopharmaceutical Co. Ltd. A

SHG:688076 China Biotechnology
Market Cap
$1.28 Billion
CN¥8.73 Billion CNY
Market Cap Rank
#7616 Global
#1649 in China
Share Price
CN¥27.54
Change (1 day)
+0.11%
52-Week Range
CN¥26.21 - CN¥40.22
All Time High
CN¥90.43
About

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was… Read more